A Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis

Study acronym: DekaJoint
StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment increased: 42 → 54 participants Show 4 more changesShow less
    • Eligibility criteria expanded, about 41 words
    • Secondary endpoints: details revised at 4 of 6 entries
    • Study description expanded, about 60 words
    • Site details revised at 1 of 2 sites
  2. Start date changed from estimate of Jan 2026 to Mar 4, 2026v3
  3. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Study sites: 1 to 2
    • Start date: Dec 2025 to Jan 2026
    • Eligibility criteria expanded, about 29 words
    • Secondary endpoints: 5 to 6
    • Study description expanded, about 6 words
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study is to evaluate the safety of F8IL10 when administered by intra-articular injection and to determine the maximum tolerated dose (MTD) in order to establish the recommended dose (RD) in patients with Reumatoid Arthritis.
Trial Details
NCT Number NCT07245992
Lead Sponsor Philogen S.p.A.
Conditions
(from sponsor)		 Rheumatoid Arthritis (RA)
Related terms Arthritis, Rheumatoid
Enrollment 54 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov